PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Journal of Neurology0 citations

S100β and NSE as biomarkers of CNS vulnerability in patients with ICANS after CAR T-cell therapy

Early serum S100β but not neuron-specific enolase reflects baseline CNS vulnerability in ICANS after CD19 CAR T-cell therapy

View Full Paper

Authors

CRCharleen RobertAAAgusti AlentonSCSylvain Choquet

Discussion

Loading...

Member takes

Overview

Retrospective study reveals biomarkers relate to prior CNS involvement and clinical outcomes in ICANS after therapy.

Key Points

  • To assess the significance of serum biomarkers S100β and neuron-specific enolase in relation to ICANS after CD19 CAR T-cell therapy.
  • Retrospective study of adult patients treated with CD19 CAR T-cell therapy from 2020 to 2024
  • Evaluated serum dynamics of S100β and neuron-specific enolase in relation to ICANS development
  • Included patients with complete paired biomarker measurements
  • Performed multivariable analysis to assess associations with ICANS
  • 29% of patients developed ICANS at a median of 6 days post-infusion
  • Higher ΔS100β was observed in patients with ICANS compared to those without
  • Prior CNS involvement was significantly more frequent in ICANS patients
  • ΔS100β did not correlate with ICANS severity or duration
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Robert et al. (2026) studied this question.

synapsesocial.com/papers/6996712d80e1323b05ec043chttps://doi.org/10.1007/s00415-026-13698-0
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Severity‐Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19‐Targeted CAR T‐Cell Therapy2025
  2. 2NSE and S100β as serum alarmins in predicting neurological outcomes after cardiac arrest2024 · 11 citations
  3. 3Diagnostic Value of Serum Neuron-Specific Enolase and S100 Calcium-Binding Protein B for Sepsis-Associated Encephalopathy: A Systematic Review and Meta-Analysis2026
  4. 4Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy2024 · 10 citations
  5. 5Abstract 1063: Serum neuron-specific enolase (NSE) as a biomarker of central nervous system (CNS) metastases: Updated results from the BrainStorm program (Oncodistinct 006)2026